Basilea Pharmaceutica Ltd., of Basel, Switzerland, started enrollment in the first of its two planned phase III registration studies of the ceftobiprole. The first study evaluates the safety and efficacy of the antibiotic in the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI).